11
Participants
Start Date
November 29, 2023
Primary Completion Date
July 10, 2024
Study Completion Date
July 10, 2024
Tofacitinib 5 MG
Participants in the research will receive oral Tofacitinib medication with a dosage of 5 mg, twice a day, for 12 weeks. They will be scheduled to come for follow-up every 4 weeks throughout the 12-week period, and will continue to be followed up for 4 weeks after stopping the medication. The total duration of the research will be 16 weeks. The purpose is to evaluate the effectiveness and safety of the medication.
Hair and Nail center, Institute of Dermatology, Bangkok
Institute of Dermatology, Thailand
OTHER_GOV